Pfizer announced  that  its proposed biosimilar to Humira® (adalimumab), has demonstrated equivalent efficacy to Humira® in a clinical study.  The clinical study gathered data from a 12 week trial in which patients with rheumatoid arthritis were randomized to receive either Humira® or the proposed biosimilar, both in combination with methotrexate.

Humira, which is currently approved for several indications, generated sales of $14 billion in 2015, up 11.7% year over year.

According to the press release, Pfizer now has positive data for three proposed biosimilars.  The Pfizer biosimilars pipeline consists of eight distinct biosimilar molecules in mid to late stage development, and several others in early stage development.

Source: Press Release, The Steet, Yahoo Finance